Given the fact that 10% of patients with low TMB and PD-L1 negative staining achieved DCB in the original study (Supplementary Fig. 20d), these results suggest that 9p21 loss may serve as a biomarker that can compensate for other biomarkers including PD-L1 expression and TMB level, particularly in identifying NSCLC patients that are unlikely to benefit from PD-1/PD-L1 monotherapy. Here, CD274 is linked to non-small cell lung carcinoma.